Vesugen
A Khavinson-class Lys-Glu-Asp tripeptide bioregulator marketed for vascular endothelial health and cardiovascular anti-aging.
Vesugen is a short synthetic tripeptide (Lys-Glu-Asp) developed within Vladimir Khavinson's laboratory at the Saint Petersburg Institute of Bioregulation and Gerontology and marketed in Russia as an oral capsule for vascular and endothelial support. It is proposed to act on vascular smooth muscle and endothelium by entering cell nuclei and selectively modulating gene expression tied to endothelial function and vascular aging. Evidence is preclinical and largely limited to the Khavinson group, with no FDA approval and no Western Phase 2/3 trials. Notably, Vesugen is sequence-identical to Testagen at the tripeptide level.
Class
Synthetic tripeptide bioregulator (Khavinson short-peptide class)
Half-life
Unknown
Routes
Oral (capsule), Subcutaneous (research-chemical form)
Category
Longevity & Bioregulators
Researched benefits
What it's studied for
Vascular repair and vessel-wall support
Vesugen is marketed specifically for the vessel wall (as opposed to Cardiogen for the myocardium), with preclinical claims of reduced lipid accumulation and improved structural parameters in aging vascular tissue. Evidence is preclinical and largely from the Khavinson group.
Endothelial function
Proposed to modulate endothelial gene programs including endothelial nitric oxide synthase (eNOS) and endothelial growth factors, theoretically improving nitric oxide bioavailability and vessel relaxation. Documented at the level of endothelial cell-culture gene expression markers rather than Western clinical endpoints.
Cardiovascular anti-aging
Positioned within the Khavinson framework as a geroprotective bioregulator that may partially reset the endothelial transcriptional program toward a younger pattern in age-related vascular decline. Class-level reviews document geroprotective effects in animal models.
Atherosclerosis / lipid deposition reduction
Preclinical descriptions attribute reduced atherogenic lipid deposition in the vessel wall to normalized gene expression in endothelial and smooth muscle cells. This is a theoretical, mechanism-based claim, not an outcome demonstrated in controlled human trials.
Modest blood pressure effects
Small Russian observational studies report systolic and diastolic reductions on the order of a few mmHg after 10-day oral cycles in older adults with mild age-related hypertension, an effect size that overlaps with lifestyle change and measurement noise.
Mechanism
How it works
Vesugen's proposed action follows the three-stage Khavinson short-peptide framework. Stage one is absorption from the gut and passive crossing of cell membranes into target tissue. Stage two is passive nuclear import, with the small peptide entering cell nuclei and reaching chromatin. Stage three is sequence-selective binding to DNA regulatory regions associated with vascular and endothelial gene programs, proposed to normalize gene expression in endothelial and vascular smooth muscle cell populations.
In Vesugen's case the claimed target tissue is vascular smooth muscle and endothelium, with proposed effects on endothelial nitric oxide synthase (eNOS), endothelial growth factors, pro- and anti-inflammatory gene regulation, and the chromatin state of aging endothelial cells. The central claim is that cycled dosing can shift the endothelial transcriptional program toward a younger pattern, improving nitric oxide bioavailability, vessel relaxation, and resistance to atherogenic lipid deposition.
Class-level published research on Khavinson short peptides has characterized systematic gene-expression regulatory effects and cell-differentiation regulatory capacity across multiple tissue types, providing the mechanistic framework within which Vesugen's vascular effects are proposed. However, the biochemical basis for short-peptide tissue selectivity remains contested in mainstream molecular biology, and the pharmacokinetic claim that orally delivered tripeptides survive gastric proteolysis and reach vascular nuclei at gene-regulatory concentrations is not independently established. The mechanism should be understood as a theoretical model rather than settled biochemistry.
A key structural note: Vesugen is sequence-identical to Testagen — both are Lys-Glu-Asp tripeptides. The Khavinson framework attributes their different proposed tissue targets (vascular for Vesugen, testicular for Testagen) to context-dependent effects rather than any sequence difference, meaning mass spectrometry alone cannot distinguish the two molecules.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
The commercial product is an oral capsule and requires no reconstitution — it is swallowed whole with water on an empty stomach; chewing or breaking is discouraged because the excipient matrix is designed for intact gut delivery. An injectable research-chemical form also exists: a typical 10 mg vial reconstituted with 2 mL bacteriostatic water yields 5 mg/mL (5000 mcg/mL), so 100 mcg = 0.02 mL (2 units), 200 mcg = 0.04 mL (4 units), 300 mcg = 0.06 mL (6 units) on a U-100 insulin syringe. Trickle the water down the vial wall, swirl gently (do not shake), refrigerate reconstituted solution at 2-8 C and use within 14-30 days.
Beginner
- Dose
- 1 capsule (20 mg nominal powder, approx. 2-4 mg peptide)
- Frequency
- Once daily
- Timing
- Empty stomach in the morning with water, 15-30 min before food
- Duration
- 10 consecutive days, then 60-90 day washout; up to 2 cycles in the first year
- Route
- Oral
Complete a baseline cardiovascular workup first (home BP, lipid panel, glucose/HbA1c, kidney and liver function, CBC, TSH). Run Vesugen as a solo variable on a stable regimen and log BP twice daily, resting heart rate, and symptoms.
Intermediate
- Dose
- 2 capsules (40 mg nominal, approx. 4-8 mg peptide)
- Frequency
- Daily, split morning and early afternoon
- Timing
- Empty stomach
- Duration
- 10 consecutive days, 60-90 day washout; up to 3 cycles per year
- Route
- Oral
For users with at least one tolerated cycle and clinician awareness. Maintain an evidence-graded baseline vascular stack between cycles; monitor lipids and HbA1c every 6 months. Watch orthostatic BP closely in those on multi-drug antihypertensive regimens.
Advanced
- Dose
- 2-3 capsules (40-60 mg nominal, approx. 4-12 mg peptide)
- Frequency
- Daily, split morning and afternoon
- Timing
- Empty stomach
- Duration
- 10 consecutive days, 60-90 day washout; up to 4 cycles per year
- Route
- Oral
No dose-ranging data supports more than 2 capsules/day; forum reports suggest no consistent added benefit at higher doses. Only for experienced users with documented cycles and stable labs. Some run multi-peptide Khavinson stacks, though no trial evidence supports stacking over single-peptide cycling.
Injectable (research-chemical)
- Dose
- 100-300 mcg
- Frequency
- Once daily
- Timing
- Morning
- Duration
- 10-20 day cycle, then 60-90 day washout
- Route
- Subcutaneous (abdomen or anterior thigh)
Research-chemical formulation, not the commercial capsule. Less studied than oral cycling and carries additional risks (sterile technique, dose uncertainty). The conservative recommendation across sources remains oral capsule use for almost all users.
- The 20 mg on the capsule label refers to total powder weight (milk-protein and starch excipients), not peptide dose; each capsule contains only roughly 2-4 mg of synthetic peptide.
- The 10-days-on / 60-to-90-days-off cycling convention is a Khavinson tradition rather than a pharmacokinetically derived schedule; no data compare it to longer or continuous dosing.
- Dosing is not differentiated by goal (hypertension vs. lipids vs. endothelial function) or by concurrent cardiovascular medications in the published data.
- Do not crush and dissolve commercial oral capsules for injection — the excipient matrix is not sterile and not formulated for parenteral use.
- Never mix Vesugen with another peptide in the same syringe; inject separate peptides at separate sites.
- Sealed capsule bottles keep in a cool dry place (refrigeration extends shelf life once opened); typical shelf life is about 24 months. Skip missed doses rather than doubling up.
- Vesugen is best framed as a low-priority optional adjunct to a real cardiovascular prevention plan (lifestyle, evidence-based pharmacology, screening, clinician relationship), not a substitute for statins, antihypertensives, or antiplatelets.
Evidence
Research & clinical studies (2)
Peptide Regulation of Gene Expression: A Systematic Review
Documents the gene-expression regulatory properties of short peptides including Vesugen (Lys-Glu-Asp), showing chromatin-binding activity and selective gene modulation in endothelial and vascular smooth muscle cells relevant to vascular aging and endothelial health.
PMID 34834147Short Peptides in the Treatment of Age-Related Diseases
Summarizes geroprotective properties of short regulatory peptides including Vesugen, documenting effects on vascular tissue function, endothelial health, and longevity outcomes in animal models, with Khavinson-program clinical observations of reduced age-related vascular pathology.
PMID 31808038Combinations
Stacking & blends
Vascular + Cardiac Bioregulator Pair
Combined vascular wall and cardiac muscle support
Cardiogen is the companion cardiac peptide to Vesugen's vessel-wall target; the two are commonly paired in users with both cardiac and vascular concerns and are flagged as synergistic in interaction matrices.
Longevity Rotation
Distribute bioregulator exposure across cardinal aging axes over a year
A common intermediate rotation cycles Vesugen (vascular), Cardiogen (cardiac), Pinealon (neurological), and Epithalon (pineal/longevity) across four sequential cycles to cover multiple tissue systems.
Vascular + Regenerative Support
Layer endothelial gene-regulation with copper-peptide tissue support
GHK-Cu is listed as compatible with Vesugen and is used adjunctively for regenerative and vascular-supportive aims, though no controlled evidence establishes added benefit.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Pregnancy and breastfeeding
- Known hypersensitivity to short-peptide bioregulators or capsule excipients (milk-protein isolates, starch)
- Active critical illness or acute systemic infection (e.g., sepsis)
- The week before and after any scheduled surgery requiring hemostasis
- History of significant GI bleeding, hemorrhagic stroke, or inherited bleeding disorder
- Decompensated heart failure, unstable angina, or recent stroke/MI (within 3 months)
- Atrial fibrillation on anticoagulation or mechanical heart valve without cardiologist input
- Severe uncontrolled hypertension (>180/110) or hyperlipidemia (LDL-C >190 mg/dL) pending therapy
- Advanced liver disease (Child-Pugh B/C cirrhosis) or severe CKD (eGFR <30)
- Children and adolescents
Published Khavinson-group observations describe Vesugen as well tolerated, but the evidence base is small and short (tens of patients, weeks to months, rarely placebo-controlled), so 'well tolerated' is provisional. Theoretical interaction concerns include additive hypotension with antihypertensives, PDE5 inhibitors, alpha-blockers, and nitrates (monitor home blood pressure); additive platelet inhibition with antiplatelets; and uncharacterized effects in anticoagulated patients (discuss with cardiology/hematology). No known interaction with statins, ezetimibe, PCSK9 inhibitors, SGLT2 inhibitors, or GLP-1 agonists. Long-term safety beyond a year or two of repeated cycling is not documented.
FAQ
Vesugen — common questions
What is Vesugen and how is it supposed to work?
Vesugen is a synthetic Lys-Glu-Asp tripeptide from the Khavinson bioregulator family, marketed in Russia as an oral capsule for vascular and endothelial support. It is proposed to enter vascular cell nuclei and selectively bind DNA regulatory regions, modulating endothelial gene expression, nitric oxide synthase activity, and markers of vascular aging. Evidence is preclinical and largely from the Khavinson group without Western Phase 2/3 trials.
Is Vesugen the same compound as Testagen?
At the peptide-sequence level, yes — both are Lys-Glu-Asp tripeptides. The Khavinson framework attributes their different proposed tissue targets (vascular for Vesugen, testicular for Testagen) to context-dependent effects rather than sequence differences. Because mass spectrometry cannot distinguish them, buyers purchasing both as separate compounds are effectively paying twice for the same molecule.
What is the standard Vesugen cycle and dose?
The standard Khavinson-framework cycle is 1 to 2 capsules (20 mg nominal each, approximately 2-4 mg peptide per capsule) daily for 10 consecutive days, followed by a 60-90 day washout, typically 2 to 4 cycles per year. Capsules are taken on an empty stomach in the morning with water. There is no dose-ranging data supporting more than 2 capsules daily.
Does Vesugen lower blood pressure?
Small Russian observational studies report modest reductions on the order of a few mmHg systolic and diastolic after 10-day oral cycles in older adults with mild age-related hypertension — a small change that overlaps with lifestyle effects and measurement noise. It is not a substitute for evidence-based antihypertensive therapy, which reliably produces 10-20 mmHg systolic reductions with decades of outcome data.
Does Vesugen replace statins or cardiovascular medications?
No. Vesugen has no Western regulatory approval, no Phase 3 outcome trials, and no evidence for cardiovascular event reduction, whereas statins, PCSK9 inhibitors, ezetimibe, SGLT2 inhibitors, and GLP-1 agonists all have outcome-trial evidence. Anyone on cardiovascular therapy should continue it and consider Vesugen only as a layered experimental adjunct.
What are the side effects of Vesugen?
Published observations describe it as well tolerated, with occasional mild GI discomfort, infrequent transient headache, and rare early-cycle flushing. Theoretical concerns include additive hypotension in those on multi-drug antihypertensive regimens and additive antiplatelet effect in those on aspirin or P2Y12 inhibitors. The capsule excipients include milk-protein isolates, relevant to those with milk allergy or lactose intolerance.
Is Vesugen legal to purchase?
Vesugen is legal to purchase as a research chemical for laboratory use in most jurisdictions, and it is sold over-the-counter as a supplement in Russia and Eastern Europe. It is not approved for human consumption in the US, EU, or most Western markets and has no active FDA approval pathway.
How long until I would see effects from Vesugen?
Responders often report subjective changes (energy, exercise tolerance, extremity warmth) within the 10-day cycle, consolidating over the following 30 days. Objective blood pressure and heart-rate changes are typically measurable during and just after cycling; lipid changes are best assessed 2-3 months after cycle end. Realistic expectations are small changes that are hard to separate from concurrent lifestyle modifications.
